In May 2005, Steve Bollinger was to become president and chief operating officer of Pervasis Therapeutics, a small cell therapy start in Cambridge, Massachusetts. If proven successful, the product Pervasis, Vascugel, can change the way the disease treatment and have serious consequences in a large and underserved population. However, Vascugel not yet gone into human clinical trials, and get it on the market will mean navigating the approval process FDA, as well as raising the capital needed to finance the operation. That was before Bollinger decide on a strategy for clinical trials Vascugel author. In addition, he will have to decide how much money the company has to increase, taking into account the interests of the company's founders and existing venture investors. Finally, while Bollinger, is expected to lead the company in the next two to three years, the board Pervasis "plans to launch a permanent CEO search in the future." Hide
by Robert F. Higgins, Virginia A. Fuller Source : Harvard Business School 29 pages. Publication Date: December 21, 2006. Prod. #: 807026-PDF-ENG
Related Case Solutions & Analyses:
Maskwa Resources: Financing with a Euro Bond
Hertz Corporation (A)
Euro Takeover 2005 (A) The Target: HoogenFood N.V.
Calpine Corporation
Tapestry Networks
The Sustainability Accounting Standards Board
Corporate governance reforms and our regulatory future
International Payment Methods
COST OF CAPITAL IN 2012
Prudential UK: Rebuilding A Mighty Business
